NEW YORK, NY / ACCESSWIRE / July 31, 2018 / U.S. markets continued to drop on Monday, as tech sector close in the red weighed by majority of the FAANG (Facebook, Apple, Amazon, Netflix and Google parent Alphabet) stocks. The Dow Jones Industrial Average fell 0.57 percent to close at 25,306.83, while the S&P 500 Index was down 0.58 percent to close at 2,802.60. The Nasdaq Composite Index declined 1.39 percent to close at 7,630.00.

“The market is punishing companies that don’t beat on revenue or earnings, or which give a bad outlook. You need to win on all three to do well, and if you miss, like Facebook did, you get pummeled,” said director of global market research at Boston Partners, Michael Mullaney.

RDI Initiates Coverage on:

First Data Corporation
https://rdinvesting.com/news/?ticker=FDC

Nielsen Holdings plc
https://rdinvesting.com/news/?ticker=NLSN

First Data’s stock jumped 3.18% Monday, to close the day at $23.34. The stock recorded a trading volume of 15,758,434 shares, which was above its three months average volume of 7,294,739 shares. In the last year, First Data’s shares have traded in a range of 14.73 – 24.25. The share price has gained 58.45% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $21.92 is above its 200-day moving average of $18.26. Shares of the company are trading at a Price to Earnings ratio of 14.36. Shares of First Data have gained roughly 11.51 percent in the past month and are up 39.68 percent year-to-date.

Access RDI’s First Data Corporation Research Report at:
https://rdinvesting.com/news/?ticker=FDC

On Monday, shares of Nielsen Holdings recorded a trading volume of 7,846,972 shares, which was above the three months average volume of 4,128,376 shares. The stock ended the day 3% higher at $23.03. The share price has fallen 47.19% from its 52 week high with a 52 week trading range of 20.53 – 43.61. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $30.31 is below its 200-day moving average of $32.30. Shares of the company are trading at a Price to Earnings ratio of 19.19. Shares of Nielsen Holdings have fallen roughly 25.54 percent in the past month and are down 36.73 percent year-to-date.

Access RDI’s Nielsen Holdings plc Research Report at:
https://rdinvesting.com/news/?ticker=NLSN

Our Actionable Research on First Data Corporation (NYSE :FDC) and Nielsen Holdings plc (NYSE :NLSN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507504

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Texas Roadhouse and Nutrisystem both saw losses in Monday’s trading session after reporting quarterly results. While Texas Roadhouse missed on earnings, Nutrisystem had beat expectations on both the top and bottom line but closed down a little over 2%.

RDI Initiates Coverage on:

Texas Roadhouse, Inc.
https://rdinvesting.com/news/?ticker=TXRH

Nutrisystem, Inc.
https://rdinvesting.com/news/?ticker=NTRI

Texas Roadhouse, Inc. shares closed down 2.61% on Monday with bigger losses after the market closed. The stock dropped 12.03% in after-hours trading. It was an earnings miss that sent shares of the American chain restaurant that specializes in steaks and promotes a Western theme, into the red yesterday. The company missed on both the top and the bottom line in the second quarter. Net income of $44.2 million, or 62 cents per share, was compared to $37.6 million, or 53 cents a share in the year ago period. Revenue was 629.2 million. Analysts were waiting for earnings of 68 cents a share on revenue of $634.5 million. Kent Taylor, Chief Executive Officer commented, “Our top-line results for the second quarter were strong with double-digit revenue growth, including 5.7% comparable restaurant sales growth. We are pleased with the consistency of our traffic gains this year and the continued strength headed into the third quarter. On the development front, with 14 company restaurants opened in the first half of 2018, we are on track to open 27 or 28 restaurants for the year. We continue to fund our new restaurant growth through internal cash flow, while also returning excess capital to our shareholders through dividends, further driving shareholder value.”

Access RDI’s Texas Roadhouse, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TXRH

Nutrisystem, Inc. shares closed down 2.04% on Monday with an additional loss of 1.56% after the close. The share price dropped despite the commercial provider of weight loss products and services reporting its second quarter financial report revealing earnings per share of 87 cents. Analysts had been expecting just 81 cents. Nutrisystem has surpasses estimates for EPS four straight quarters in a row. Revenue of $191.3 million in the period also beat the $188.4 million expected by analysts. Dawn Zier, President and Chief Executive Officer, stated, “We’re pleased to have exceeded second quarter guidance. Our multi-brand strategy, supported by two highly recognized names in the health and wellness industry, is working well and provides a strong, scalable platform for future growth. Our announcements around the recently launched DNA Body Blueprint™ and the branded lines of vitamin packs showcase our focus on science-backed personalized nutrition to drive not only weight loss, but overall health. We believe our efforts to date, coupled with second-half investments in our innovation pipeline, branding and digital media expansion, will pave the way for meaningful growth and profitably expand customer reach in 2019 and beyond.”

Access RDI’s Nutrisystem, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NTRI

Our Actionable Research on Texas Roadhouse, Inc. (NASDAQ: TXRH) and Nutrisystem, Inc. (NASDAQ: NTRI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507498

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Shares of US Foods Holding collapsed on Monday after reporting an earnings and revenue miss in its second quarter report and announcing that it will acquire SGA’s Food Group of Cos for $1.8 billion in an all cash transaction. Shares of Chipotle fell hard yesterday as well after it was revealed the company had closed an Ohio location after people fell ill.

RDI Initiates Coverage on:

US Foods Holding Corp.
https://rdinvesting.com/news/?ticker=USFD

Chipotle Mexican Grill, Inc.
https://rdinvesting.com/news/?ticker=CMG

US Foods Holding Corp. shares plunged on Monday to close down 17.46%. The stock traded explosive volume of 13,675,277 shares compared to an average trading volume of around 1.9 million shares. The drop came after the company announced second quarter financial results as well as an acquisition. For the second quarter, US Foods reported that revenue was flat at $6.2 billion. Net income for the period saw a 94% increase to hit $126 million, or 57 cents a share on an adjusted basis. Analysts however had been expecting revenue of $6.3 billion and earnings per share of 58 cents. The company also announced the acquisition of SGA’s Food Group of Cos for $1.8 billion in cash. “This acquisition will significantly increase US Foods’ reach across key markets in the attractive and growing Northwest region of the U.S. and adds one of the most well-regarded regional distributors to our company,” stated US Foods Chairman and CEO Pietro Satriano. “With a shared commitment to customer service, including a proven track record of leveraging technology and private brands to meet customer needs, SGA’s Food Group of Companies is an ideal fit. The company’s unique merchandising programs, mature local sourcing capabilities and track record of operational excellence will be strong additions to our business. We look forward to welcoming the talented teams at SGA’s Food Group of Companies to US Foods, providing customers with even better service and expanded capabilities, and delivering accelerated growth and value to our shareholders.”

Access RDI’s US Foods Holding Corp. Research Report at:
https://rdinvesting.com/news/?ticker=USFD

Chipotle Mexican Grill, Inc. shares closed down 1.45% with an additional 3.33% more in losses in after hours trading on Monday. The burrito fast food chain saw its shares drop after a report revealed that a company restaurant in Ohio had been closed after several customers became ill. Several customers had said they were ill over the weekend and yesterday after eating at the Powell, Ohio location according to Business Insider. Chipotle said on Monday that the restaurant would be re-opened today pending health department approval. “We acted quickly and closed this single restaurant out of an abundance of caution and we are working with the local health officials to reopen this restaurant as soon as possible,” said a Chipotle spokeswoman via email. “Our protocols identified a handful of illness reports at one restaurant in Powell, OH,” Chipotle spokeswoman Laurie Schalow told CNBC.

Access RDI’s Chipotle Mexican Grill, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CMG

Our Actionable Research on US Foods Holding Corp. (NYSE: USFD) and Chipotle Mexican Grill, Inc. (NYSE: CMG) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507499

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Largo Resources Ltd. (OTCQX: LGORF), a Toronto-based strategic mineral company focused on the production of vanadium flake, high purity vanadium flake and high purity vanadium powder at the Maracás Menchen Mine located in Bahia State, Brazil.

On July 17th, 2018, the company provided guidance on its expected revenue for the three-month period ending June 30, 2018, anticipating revenue of between CDN$99 million and CDN$107 million, a new quarterly revenue record for the Company.

In March 2018, the company shares were trading at $.86 and have almost doubled since that time.

The vanadium market, analyst review and targets READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/largo-resources/

The fundamental situation for vanadium is rapidly improving, with V2O5 prices continued to edge higher, which could put the company in a good starting position for the third quarter. Management continues to remain very optimistic for the year ahead as the Company begins the construction phase of the Maracás Menchen Mine expansion plan which will see capacity increase at the mine from a total of 800 tonnes produced per month of V2O5 to 1,000.

Q2 guidance, current financials and company review READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/largo-resources/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 507420

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after announcing that the FDA has approved the New Drug Application for AZEDRA.

RDI Initiates Coverage on:

Progenics Pharmaceuticals, Inc.
https://www.rdinvesting.com/report/?ticker=PGNX

ARCA biopharma, Inc.
https://www.rdinvesting.com/report/?ticker=ABIO

Progenics Pharmaceuticals, Inc. shares closed up 8.49% on about 1.7 million shares traded yesterday. The company announced that the FDA has approved the New Drug Application for AZEDRA ( iobenguane I 131) 555 MBq/mL injection for intravenous use. AZEDRA is a radiotherapeutic that is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. It is the first and only therapy that has been approved for this indication. The trial’s lead investigator, Dr. Daniel Pryma stated, ” AZEDRA is a true breakthrough in treating pheochromocytoma and paraganglioma delivering an effective anticancer therapy to these tumors. With this innovative, rationally designed treatment, we finally have a therapeutic option that helps address patients’ needs.” CEO of Progenics, Mark Baker, said, “As the first FDA approved therapy for unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy, AZEDRA provides a new treatment option for physicians and their patients. AZEDRA has been shown to decrease the need for blood pressure medication and reduce tumor size in some patients. We are extremely grateful to the patients, their families and the investigators who participated in AZEDRA’s clinical development program. We also thank those who have contributed to the development of AZEDRA over many years.” The press release also stated that AZEDRA can cause serious side effects including risk from radiation exposure, bone marrow problems and other cancers (myelosuppression and secondary malignancies), thyroid problems (hypothyroidism), elevations in blood pressure, kidney problems (renal toxicity), respiratory problems (pneumonitis), pregnancy warning (embryo-fetal toxicity), and fertility problems.

Access RDI’s Progenics Pharmaceuticals, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=PGNX

ARCA biopharma, Inc. shares closed up nearly 41% on Monday with roughly 5 million shares traded. The company had no news or catalyst to explain the unusual activity. It was about two months ago that the biopharma company had announced data from the GENETIC-AF clinical trial at the European Society of Cardiology Heart Failure 2018 World Congress in May. Per the company’s press release, in the overall study population of heart failure patients who were at high risk for recurrent atrial fibrillation (AF), pharmacogenetic guided GencaroTM did not reduce AF/AFL/ACM recurrence compared to the active comparator TOPROL-XL. However, in U.S. patients (48% of the entire cohort), a trend for potential benefit in favor of Gencaro (approximately 30% risk reduction over TOPROL-XL), was observed for the primary endpoint of all-cause mortality (ACM) or time to recurrence of AF or atrial flutter (AFL). Chairman of the Steering Committee, Dr. William T. Abraham, commented, “With additional analysis of the trial data, and taking into consideration recent studies in animal models of AF, it is likely that AF-HFrEF phenotypic differences are responsible for the heterogeneity in treatment response observed. These Phase 2B data support and provide guidance for potential additional development of Gencaro as a treatment for atrial fibrillation in patients with heart failure, an indication for which there are currently no FDA approved therapeutics.”

Access RDI’s ARCA biopharma, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=ABIO

Our Actionable Research on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and ARCA biopharma, Inc. (NASDAQ: ABIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507495

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Netflix shares entered red territory on Monday after reports revealed that Walmart is considering its own streaming service and is consulting with a cable-industry veteran over the service. Shares of Apple also saw a slight close in the red as Wall Street eagerly awaits the company’s third quarter financial results.

RDI Initiates Coverage on:

Netflix, Inc.
https://rdinvesting.com/news/?ticker=NFLX

Apple Inc.
https://rdinvesting.com/news/?ticker=AAPL

Netflix, Inc. shares closed down 5.70% on about 17.5 million shares traded yesterday. The stock’s drop came after a Wall Street Journal report said that Walmart is considering entering the video streaming service and may be launching its own. According to the report, Walmart has been consulting with Mark Greenberg, a cable-industry veteran over introducing a streaming service that has programming and tier prices that would market to the middle of the U.S. The article made sure to note that there has not been any confirmation that the project is a go but a decision could be made by the end of the summer or early fall. Variety has reported that the streaming service’s content would be targeted at Middle America with a low subscription price. Walmart is considering an $8 a month price which is $2 cheaper than Netflix.

Access RDI’s Netflix, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NFLX

Apple Inc. shares closed down a modest 0.56% on about 18.7 million shares traded. The iPhone maker will be reporting its earnings after the bell today and Wall Street is anticipating the results and especially wants to find out when the company’s next-generation iPhones are expected. Analysts chimed in this week on what they are expecting. On average, analysts expect the company to report $2.18 a share with sales of $52.34 billion for the third quarter. Analysts are also expecting the company to report 41.8 million iPhone unit sales compared to 41 million in the year ago quarter. Timothy Arcuri, an analyst with UBS remarked, “Apple is having success moving buyers up the iPhone price curve.” According to the analyst, 26% of customers had paid over $900 for an iPhone in the March quarter. In the quarter a year ago, this figure was only 5%. Arcuri is expecting iPhone average selling prices to move up again in the September quarter. He has a “buy” rating on the stock with a $210 price target. Analyst Brian White with Monness Crespi Hardt remarked, “We are not expecting any fireworks during this earnings report given the uncertainty inherent with any new iPhone launch that is usually reflected in Apple’s September-quarter guidance, combined with an onerous foreign exchange headwind. However, we believe Apple’s strong software capabilities, expanding services business and unique digital ecosystem at large are increasingly being appreciated by the market. “The stock is up a little under 12% YTD and has seen gains of around 47% in 2017.

Access RDI’s Apple Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AAPL

Our Actionable Research on Netflix, Inc. (NASDAQ: NFLX) and Apple Inc. (NASDAQ: AAPL) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507497